Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 42

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
	)

			Income tax expense

			-

			-

			800

			800

			Net loss

			(1,749,464
			)

			(1,668,212
			)

			(4,957,165
			)

			(5,207,994
			)

			Exchange differences on translation

			164,611

			1,612

			119,536

			(10,143
			)

			Net comprehensive loss

			$
			(1,584,853
			)
			 
			$
			(1,666,600
			)
			 
			$
			(4,837,629
			)
			 
			$
			(5,218,137
			)

			Weighted average number of common shares

			7,022,678

			3,221,806

			5,217,343

			3,180,647

			Loss per common share - basic and diluted

			$
			(0.25
			)
			 
			$
			(0.52
			)
			 
			$
			(0.95
			)
			 
			$
			(1.64
			)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

4

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Cash Flows

			Nine Months Ended 

			June 30, 2025

			June 30, 2024

			Cash flows from operating activities:

			Net loss

			$
			(4,957,165
			)
			 
			$
			(5,207,994
			)

			Adjustments for:

			Depreciation and amortization

			93,405

			141,843

			Share-based compensation

			325,217

			443,559

			Gain on loan forgiveness

			-

			(14,766
			)

			Changes in working capital items:

			Accounts and other receivable

			(18,159
			)

			71,501

			Prepaid expenses and other current assets

			73,355